Management Insights for Patients With Hemophilia

Now Viewing

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

Russell P. Gollard, MD, FACP: We have approximately 3 dozen patients in our plan with hemophilia A. Many of those patients present with either a family history or with a proclivity toward bleeding. In young people with severe disease, OOftentimes, this will be something that’s identified at birth when the umbilicus is cut. Other than that, we see playground injuries. We see epistaxis quite often. In young ladies, we will oftentimes see some excessive menstruation. Now, I should say that as this is a sex-linked disease, it’s much more common in males than in females, but there are women with the disease.

In our plan, we manage treatments for rare diseases. These patients are not referred out of state. We are in Las Vegas, Nevada. There is a hemophilia treatment center here that we work with, but we also manage those patients through our own clinics. These patients need to be identified and followed. They are seen in the clinic with some frequency. In some cases, they’re seen at a hemophilia treatment center where there is a full-time nurse practitioner practicing. Many of these patients are very, very active in the management of their own disease and know how to prophylax themselves. Usually, patients get 1 of the newer monoclonal factor 8 products, and these are then given with some frequency, sometimes 3 times a week, sometimes less, depending on the severity of the disease and its penetrance in these patients.

Transcript is AI generated and reviewed by an AJMC editor.